Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG.
A total of 21 patients received intravesical BCG for the prevention of recurrence of superficial transitional cell carcinoma of the bladder. Twelve patients received the Glaxo strain and 9 the Pasteur strain of the bacillus. Although thought to have different anti-tumour activities owing to a difference in antigenicity, these 2 strains produced similar tumour-free rates at 5 years' mean follow-up with an overall tumour-free rate of 43%.
Mukherjee
A
A
Department of Urology, Royal Infirmary, Bristol.
Persad
R
R
Smith
P J
PJ
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000145:classification / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine